INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,872,746 | -13.6% | 208,730 | +5.0% | 3.30% | -15.3% |
| Q2 2023 | $12,583,140 | +85.8% | 198,723 | +58.9% | 3.89% | +39.2% |
| Q1 2023 | $6,770,645 | -8.9% | 125,035 | -10.9% | 2.80% | +31.5% |
| Q4 2022 | $7,428,169 | +17.3% | 140,366 | +3.1% | 2.12% | -0.8% |
| Q3 2022 | $6,334,000 | -64.7% | 136,126 | -56.6% | 2.14% | -61.2% |
| Q2 2022 | $17,921,000 | -5.2% | 313,962 | +1.7% | 5.52% | -29.4% |
| Q1 2022 | $18,897,000 | +85.2% | 308,819 | +58.4% | 7.82% | +89.1% |
| Q4 2021 | $10,206,000 | +168.7% | 195,000 | +91.4% | 4.14% | +92.6% |
| Q3 2021 | $3,798,000 | -17.8% | 101,890 | -10.0% | 2.15% | +4.1% |
| Q2 2021 | $4,623,000 | +4.7% | 113,258 | -13.0% | 2.06% | -14.4% |
| Q1 2021 | $4,415,000 | -30.6% | 130,117 | -34.9% | 2.41% | -34.8% |
| Q4 2020 | $6,360,000 | – | 200,000 | – | 3.70% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |